



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Transplantation

**Manuscript NO:** 50424

**Title:** Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation

**Reviewer's code:** 04382473

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Instructor

**Reviewer's country:** United States

**Author's country:** Canada

**Reviewer chosen by:** Ying Dou

**Reviewer accepted review:** 2019-07-24 23:07

**Reviewer performed review:** 2019-07-24 23:11

**Review time:** 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

1) please specify what was bleeding % in abstract 2) were the 3 who bled on high dose or low dose NoAC? 3) excellent you looked at pre and post Tacro and sCr levels, can you run a similar analysis for eGFR? as that maybe a better measure of renal function. 4) well done study.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Transplantation

**Manuscript NO:** 50424

**Title:** Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation

**Reviewer's code:** 00504828

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Adjunct Professor, Doctor, Research Associate

**Reviewer's country:** United States

**Author's country:** Canada

**Reviewer chosen by:** Ying Dou

**Reviewer accepted review:** 2019-07-21 23:13

**Reviewer performed review:** 2019-07-26 22:50

**Review time:** 4 Days and 23 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

The manuscript may be the first study addressing the efficacy and safety of NOACs. Thus, it adds new information to the field. It would be better if the authors can emphasize the advantage of NOACs in comparison to the other drugs; no effect on kidney function (especially in “discussion”). In that way, audience can realize the value of the study better. • Minor grammatical errors such as “...study that addresses...” (page 10). Please thoroughly check the text.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Transplantation

**Manuscript NO:** 50424

**Title:** Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation

**Reviewer's code:** 02461826

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer's country:** Austria

**Author's country:** Canada

**Reviewer chosen by:** Ying Dou

**Reviewer accepted review:** 2019-07-22 07:12

**Reviewer performed review:** 2019-07-30 17:41

**Review time:** 8 Days and 10 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The present manuscript reports a retrospective analysis of the efficacy and safety of NOACs after kidney transplantation. Data are presented on 42 patients who received either apixaban, rivaroxaban or dabigatran for either atrial fibrillation or thromboembolism and were followed for 1 year. In general, the data on NOACs in kidney transplant patients bear novelty, however the data presentation and interpretation needs attention. - The analysis only includes patients with a eGFR of >54. Therefore, no dosage adaptation should be necessary for NOACs. This is also why the data can only be interpreted in terms of sufficiently preserved kidney function. This has to be mentioned in the discussion section and has to be compared to published data. - Why did you use only 15mg of rivaroxaban instead of 20mg although the GFR was >50ml/min? - It is not understandable why the patients were subdivided according to age extensively. It would make more sense to compare patients <75/≥75 years of age since this is 1) relevant for indication of oral anticoagulation and 2) may have an impact on the NOAC dosage. - In addition, it is very important to clearly indicate which NOAC was used with what kind of immunosuppression. - Did the patients also receive MMF and/or steroids? Please indicate. - The analysis does not have a group for comparison. It would extremely strengthen the analysis if the authors would add a matched cohort of kidney transplant recipients on vitamin K antagonists. - The use of dabigatran together with CNIs is contraindicated due to P-gp-induction leading to increased exposure to dabigatran. Did you use dabigatran together with CNIs? Please clarify. - The discussion section is extremely short and lacks study limitations. Please discuss possible interactions with immunosuppression, limitations of your study and the current literature in view of your data in more detail. - Table 2: please specify „antiplatelet“ Abstract: - „The main indications for NOACs use in the cohort were atrial fibrillation 25 (59.5%) and venous thromboembolism 10 (23.8%).“ - should be changed to „... were atrial fibrillation in 25 patients (59.5%)...“ in the abstract and the



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

whole manuscript throughout. - „There were no significant changes in the pre- and post-NOACs tacrolimus ( $p = 0.55$ ), creatinine ( $p > 0.05$ ) and eGFR levels ( $p > 0.05$ ).“ – The meaning of this sentence is unclear. - The abstract should include information on the time period since kidney transplant (and also the main text), on median GFR prior initiation of NOACs and after 1 year of NOACs. Language polishing necessary.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No